Gain Therapeutics secures new capital

Gain Therapeutics has successfully concluded a funding round and raised €2.5 million, it was reported in a press release. Funds were received from existing investor TiVenture, a Ticino risk capital fund, as well as the new investors VitaTech and the  Helsinn Investment Fund.

Gain Therapeutics is a spin-off from Minoryx Therapeutics, a biotech company in Barcelona. The spin-off uses the Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform created by Minoryx Therapeutics. This enables the identification of brain-penetrant small molecules that provide a gain-of-function of misfolded proteins. The company’s aim is to identify molecules for the treatment of lysosomal storage disorders, which are a group of hereditary metabolic disorders. Gain Therapeutics will use this new money to advance research in this area.

According to Xavier Barri, Research Professor at Gain Therapeutics, this funding will enable the company to “further support the development of our most advanced programs and namely GM1 Gangliosidosis, Gaucher Disease and GBA-related Parkinson Disease”. In addition, the capital will help accelerate the identification of clinical candidates to be tested in first-of-human studies.

Gain Therapeutics was spun-out from Minoryx Therapeutics more than a year ago and is based in Lugano. Furthermore, the company will strengthen the cooperation between Barcelona and southern Switzerland, because both are “regions with high innovation potential in the biomedical field,” as Lorenzo Leoni, Managing Partner at TiVenture and CEO of Gain Therapeutics, highlighted in a press release at the time.